Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trialDaniel V.T. Catenacci, Yung‐Jue Bang, Yoon‐Koo Kang et al.|The Lancet Oncology|2020Cited by 190
Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating <i>RET</i> Alterations and Oncogenic Signaling Pathway AberrationsThereasa A. Rich, Oliver Gautschi, Wade T. Iams et al.|Clinical Cancer Research|2019Cited by 91